Kura Oncology (NASDAQ:KURA) Receives Market Outperform Rating from JMP Securities

JMP Securities restated their market outperform rating on shares of Kura Oncology (NASDAQ:KURA) in a research report report published on Tuesday morning, Benzinga reports. The firm currently has a $32.00 target price on the stock.

A number of other brokerages have also recently commented on KURA. StockNews.com cut shares of Kura Oncology from a hold rating to a sell rating in a report on Monday, April 15th. HC Wainwright reiterated a buy rating and issued a $32.00 price target on shares of Kura Oncology in a research report on Tuesday, May 14th. Finally, Wedbush restated an outperform rating and set a $37.00 target price on shares of Kura Oncology in a research report on Friday, May 3rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average price target of $28.36.

Kura Oncology Trading Down 4.4 %

Shares of NASDAQ KURA opened at $19.77 on Tuesday. The firm’s 50 day moving average price is $20.54 and its 200-day moving average price is $18.84. The company has a market cap of $1.51 billion, a PE ratio of -9.11 and a beta of 0.94. Kura Oncology has a 52-week low of $7.41 and a 52-week high of $24.17. The company has a debt-to-equity ratio of 0.02, a quick ratio of 16.67 and a current ratio of 16.67.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.03). During the same quarter in the previous year, the firm earned ($0.50) EPS. Kura Oncology’s revenue was up .0% compared to the same quarter last year. On average, equities research analysts expect that Kura Oncology will post -2.56 EPS for the current fiscal year.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, insider Teresa Brophy Bair sold 2,615 shares of the stock in a transaction on Monday, May 20th. The shares were sold at an average price of $22.15, for a total transaction of $57,922.25. Following the completion of the transaction, the insider now owns 68,979 shares in the company, valued at $1,527,884.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 5.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Kura Oncology

Several institutional investors have recently made changes to their positions in KURA. New York State Common Retirement Fund lifted its holdings in shares of Kura Oncology by 29.1% in the 3rd quarter. New York State Common Retirement Fund now owns 23,643 shares of the company’s stock worth $216,000 after acquiring an additional 5,328 shares during the last quarter. Swiss National Bank raised its holdings in shares of Kura Oncology by 6.9% in the 3rd quarter. Swiss National Bank now owns 122,100 shares of the company’s stock valued at $1,114,000 after purchasing an additional 7,900 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Kura Oncology by 18.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 563,421 shares of the company’s stock valued at $5,138,000 after purchasing an additional 86,141 shares in the last quarter. Citigroup Inc. raised its holdings in shares of Kura Oncology by 29.3% in the 3rd quarter. Citigroup Inc. now owns 98,557 shares of the company’s stock valued at $899,000 after purchasing an additional 22,357 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale bought a new stake in shares of Kura Oncology in the 3rd quarter valued at about $262,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.